ADAR1 Capital Management LLC increased its stake in shares of GlycoMimetics, Inc. (NASDAQ:GLYC – Free Report) by 626.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 331,827 shares of the biotechnology company’s stock after acquiring an additional 286,127 shares during the quarter. ADAR1 Capital Management LLC’s holdings in GlycoMimetics were worth $83,000 as of its most recent filing with the SEC.
Separately, Wellington Management Group LLP acquired a new stake in GlycoMimetics during the fourth quarter worth approximately $352,000. 75.19% of the stock is owned by institutional investors.
Analyst Ratings Changes
GLYC has been the topic of several research reports. Cantor Fitzgerald started coverage on GlycoMimetics in a research report on Friday, March 21st. They issued an “overweight” rating on the stock. StockNews.com initiated coverage on GlycoMimetics in a report on Monday. They issued a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold”.
GlycoMimetics Trading Down 2.1 %
Shares of GlycoMimetics stock opened at $0.18 on Tuesday. GlycoMimetics, Inc. has a twelve month low of $0.14 and a twelve month high of $2.81. The company has a 50-day simple moving average of $0.26 and a two-hundred day simple moving average of $0.26.
GlycoMimetics (NASDAQ:GLYC – Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.05. Analysts predict that GlycoMimetics, Inc. will post -0.08 EPS for the current fiscal year.
GlycoMimetics Profile
GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
Recommended Stories
- Five stocks we like better than GlycoMimetics
- Why is the Ex-Dividend Date Significant to Investors?
- Options Activity Points to More Volatility for Palantir Stock
- What Are Some of the Best Large-Cap Stocks to Buy?
- NVIDIA Stock: Oversold, Undervalued — How Low Can It Go?
- How to buy stock: A step-by-step guide for beginnersÂ
- MicroStrategy Sees Insider Buy-Sell Action in Q1
Want to see what other hedge funds are holding GLYC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlycoMimetics, Inc. (NASDAQ:GLYC – Free Report).
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.
